If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humalog Summary of Product Characteristics (SmPC)
Humalog 200 Units/ml (insulin lispro): Interaction with other medicinal products
Insulin requirements may be altered by other medicinal products.
requirements may be increased by medicinal products with
hyperglycaemic activity, such as oral contraceptives,
corticosteroids, or thyroid replacement therapy, danazol, beta2
stimulants (such as ritodrine, salbutamol, terbutaline).
requirements may be reduced in the presence of medicinal products
with hypoglycaemic activity, such as oral hypoglycemics, salicylates
(for example, acetylsalicylic acid), sulpha antibiotics, certain
antidepressants (monoamine oxidase inhibitors, selective serotonin
reuptake inhibitors), certain angiotensin converting enzyme
inhibitors (captopril, enalapril), angiotensin II receptor blockers,
beta-blockers, octreotide oralcohol.
physician should be consulted when using other medicinal products in
addition to Humalog 200 units/ml KwikPen.
Kwikpen 200 units/ml
[Summary of Product Characteristics]. Utrecht, The Netherlands: Eli
Lilly Nederland B.V.
Date of Last Review:December 19, 2018
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org